A poor quarter for Roche leads to muted expectations
Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.
Covid-19 takes a toll on medtech’s first quarter
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Big Pharma remains bullish in the face of Covid-19
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
New Covid-19 test and a decent first quarter buoy Abbott
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
